Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
The purposee of this study is to determine the safety and dosing of Fenretinide when given
continuously for 5 days, every 3 weeks, in pediatric patients with recurrent and/or resistant
acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and non-Hodgkin's
lymphoma (NHL).